US-headquartered drugmaker Mylan NV would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at ₹4,800 rupees per 100 mg vial. The Drug Controller General of India approved the remdesivir version for treatment of suspected or laboratory-confirmed severe COVID-19 incidences, Mylan said on Monday. Its remdesivir version is called 'Desrem'.